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Abstract We previously reported that paclitaxel acted directly
on mitochondria isolated from human neuroblastoma SK-N-SH
cells. Here, we demonstrate that the direct mitochondrial e¡ect
of paclitaxel observed in vitro is relevant in intact SK-N-SH
cells. After a 2 h incubation with 1 WM paclitaxel, the mito-
chondria were less condensed. Paclitaxel (1 WM, 1^4 h) also
induced a 20% increase in respiration rate and a caspase-inde-
pendent production of reactive oxygen species by mitochondria.
The paclitaxel-induced release of cytochrome c was detected
only after 24 h of incubation, was caspase-independent and per-
meability transition pore-dependent. Thus, paclitaxel targets
mitochondria upstream of caspase activation, early during the
apoptotic process in intact human neuroblastoma cells.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Paclitaxel (Taxol0) is an anticancer drug highly e⁄cient in
the treatment of several malignancies [1], currently under eval-
uation for childhood tumors [2]. It is an anti-tubulin agent
that stabilizes the microtubule network and inhibits the dy-
namics of microtubules [3]. Paclitaxel induces apoptosis after
mitotic block in proliferating cells [4], but the mechanism of
paclitaxel-induced apoptosis remains unclear [5,6]. Caspases
are involved in this process [7,8] but their role has not been
fully elucidated yet [9]. Mitochondria play a key role in apo-
ptosis and mitochondrial outer membrane permeabilization is
a critical event during apoptosis. Several apoptogenic factors,
including cytochrome c (cyt c), apoptosis inducing factor, en-
donuclease G, SMAC/Diablo, procaspases, and calcium, can
be released into cytosol upon various apoptotic stimuli [10].
The molecular mechanisms by which cyt c is released remain
controversial and several models are currently proposed [10^
13]. We have previously shown that paclitaxel could act di-
rectly on isolated mitochondria from human neuroblastoma
cells to induce the permeability transition pore (PTP)-depen-
dent release of mitochondrial cyt c [14], and that this e¡ect
was probably mediated by the presence of mitochondrial tu-
bulin that interacts with the voltage-dependent anion channel
(VDAC) [15]. Varbiro et al. [16] have con¢rmed our results on
the release of cyt c triggered by paclitaxel and added that
paclitaxel could induce the production of reactive oxygen spe-
cies (ROS) or the decrease of mitochondrial membrane poten-
tial on isolated mitochondria from the HepG-2 hepatocellular
carcinoma cell line, the BRL3A rat liver cell line, and kidney,
heart and liver from rat. Recently, Kidd et al. [17] have shown
that paclitaxel could directly target PTP to modify calcium
signaling in mouse pancreatic acinar cells. We have also dem-
onstrated that the in vitro mitochondrial e¡ect of paclitaxel
mediates the antagonism in cytotoxicity observed between ar-
senic trioxide and paclitaxel on the SK-N-SH cell line [18]
indicating that the in vitro mitochondrial e¡ect of paclitaxel
could be relevant in intact cells. In the current study, we in-
vestigate the e¡ects of clinically relevant concentrations of
paclitaxel on mitochondria in intact SK-N-SH human neuro-
blastoma cells and we demonstrate that paclitaxel targets mi-
tochondria upstream of caspase activation, early during the
apoptotic process.
2. Materials and methods
2.1. Drugs and reagents
Stock solutions of paclitaxel (Sigma), betulinic acid (Calbiochem),
rotenone (Sigma), bongkrekic acid (Calbiochem) and the general
caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-promethyl ketone
(Z-VAD-fmk) (Eurobiol) were prepared in dimethylsulfoxide
(DMSO). Stock solutions of doxorubicin (Dakota) and carbonyl
cyanide-p-tri£uoromethoxyphenylhydrazone (FCCP) (Sigma) were
prepared in distilled water and ethanol respectively.
2.2. Cell culture and drug treatment
Human neuroblastoma SK-N-SH cells were cultured as described
previously [7]. Drug treatment started when cell con£uence reached
70%. Bongkrekic acid, rotenone, KCN, or Z-VAD-fmk were added
5 min before anticancer agents (paclitaxel, doxorubicin, betulinic
acid).
2.3. Analysis of mitochondrial morphology by transmission electron
microscopy
Cells were treated with 1 WM paclitaxel or DMSO (control) for 2 h
at 37‡C, ¢xed, dehydrated in ethanol, embedded in Epon, and cut into
thin sections [19]. The samples were imaged by a transmission electron
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microscope (JEOL 1220). At least 100 mitochondria were analyzed
and the cristae/matrix surface ratio was calculated using image anal-
ysis software (IPS Samba Technologies, Grenoble, France).
2.4. Respiration rate (RR) measurement
SK-N-SH cells were treated with paclitaxel or doxorubicin for 1^4 h.
Then, cells (15U106) were harvested and suspended in supplemented
growth culture medium at 37‡C. The uncoupling agent (25 WM
FCCP) and the inhibitor of mitochondrial respiration (1.2 mM
KCN) were added directly to the cell suspension during the measure-
ment of the respiration rate by using a Clark oxygen electrode [14].
2.5. ROS measurement
ROS measurement was performed using 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma) as described
[16]. SK-N-SH cells were cultured into 96 well plates, incubated
with 1 WM paclitaxel, 1.5 WM rotenone, 1.2 mM KCN, 50 WM
Z-VAD-fmk alone or in combination for 1^4 h. Formazan blue dye
formed by the e¡ect of ROS on MTT was solubilized in DMSO.
Optical densities were read with a Metertech S960 ELISA plate reader
at 550 nm. Experiments were performed three times in quadruplicate.
To con¢rm these results, a lucigenin assay based on the chemilumi-
nescence properties of lucigenin was used as previously described [20].
2.6. Western blot analysis of cytosolic cyt c
Cytosolic fraction was prepared as described [21]. The detection of
cyt c was preformed by Western blot analysis as described [17].
2.7. Immuno£uorescence visualization of cyt c
Cells were grown on 8 well plates (Labtek), incubated with di¡erent
anticancer agents alone or in combination with Z-VAD-fmk or
bongkrekic acid for up to 48 h. Cells were then permeabilized with
1% saponin, ¢xed with 3.7% paraformaldehyde, successively incu-
bated with anti-cyt c antibody (Pharmingen), and secondary antibody
coupled with £uorescein isothiocyanate (Amersham). Cells were ob-
served using a Leica DM-IRBE microscope coupled with a digital
camera (CCD camera coolsnapFX; Princeton Instruments). Two hun-
dred cells were analyzed with Metamorph software for each experi-
ment which was performed in triplicate.
3. Results
3.1. Changes in mitochondrial morphology
Apoptosis is often associated with modi¢cations of mito-
chondrial morphology [22]. Thus, we studied the e¡ect of a 2 h
Fig. 1. Mitochondrial morphology in intact SK-N-SH cells after paclitaxel incubation. A: Morphology of mitochondria in control and
paclitaxel-treated (1 WM, 2 h) SK-N-SH cells. Bar represents 500 nm. Higher magni¢cation of the boxed parts (2U) has been added. B: Cris-
tae/matrix surface ratio of mitochondrial population before and after paclitaxel treatment.
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paclitaxel treatment on mitochondrial morphology in intact
cells. As shown by electron microscopy, mitochondria are
less condensed in paclitaxel-treated cells (Fig. 1A). Paclitaxel
induces a statistically signi¢cant increase of the cristae/matrix
surface ratio of mitochondria compared to control cells
(0.22R 0.1 vs. 0.07 R 0.05, P6 0.0001) (Fig. 1B). In contrast,
no di¡erence was observed in maximum/minimum diameter
ratio between mitochondria from treated and control cells
(1.70R 0.8 vs. 1.74 R 0.7). These results show that paclitaxel
early a¡ects mitochondrial morphology without inducing
swelling. These changes in mitochondrial morphology very
likely represent an early involvement of mitochondria in
paclitaxel-induced apoptosis.
3.2. Increase in respiration rate
We checked whether the increase in RR induced by pacli-
taxel that we described in a cell-free system [14] could also be
observed in living cells. As shown in Fig. 2, paclitaxel induces
a statistically signi¢cant increase in RR (20R11%, P6 0.005).
This e¡ect started after a 1 h treatment and remained stable
for at least 4 h. When the mitochondrial uncoupler FCCP was
added to the cell suspension, an equivalent increase in RR was
observed in paclitaxel-treated and control cells (data not
shown). The total inhibition of RR induced by KCN con¢rms
the mitochondrial origin of the oxygen consumption (data not
shown). Interestingly, doxorubicin, a drug with a mechanism
of action di¡erent from that of paclitaxel, used at a concen-
tration that induces massive apoptosis [18], did not change
RR after 1^4 h treatment. These results indicate that paclitax-
el speci¢cally acts on mitochondria in living cells to induce an
increase in RR.
3.3. Increase in ROS production
As ROS production is de¢nitely implicated in apoptosis and
can be closely related to oxidative phosphorylation [23], we
then investigated the e¡ect of paclitaxel on ROS production.
Paclitaxel (1 WM, 1^4 h) induced a statistically signi¢cant
time-dependent increase in ROS production (10^40%,
P6 0.05) (Fig. 3). Inhibition of ROS production by 1.5 WM
rotenone or 1.2 mM KCN con¢rms that the ROS production
came from the respiration of mitochondria. Similar results
were obtained using the lucigenin assay: paclitaxel (1 WM,
4 h) induced a 44R 13% (P6 0.05) increase in ROS produc-
tion that was inhibited by rotenone (19R 6%; P6 0.05). Fur-
thermore, the increase in ROS production was caspase-inde-
pendent as Z-VAD-fmk did not decrease paclitaxel-induced
ROS production (Fig. 3). Thus, paclitaxel induces an early
increase in mitochondrial ROS production upstream of cas-
pase activation.
3.4. Release of cyt c
Western blot analysis of cytosolic cyt c show that no release
of cyt c was observed until after 24 h of treatment with pa-
clitaxel (Fig. 4A). These results were con¢rmed using immu-
no£uorescence experiments (Fig. 4B). Control cells have a
punctiform cyt c staining whereas cells that have released
cyt c display a di¡use staining as previously described [24].
To further investigate the mechanism of cyt c release, we pre-
treated cells with 25 WM bongkrekic acid, a PTP inhibitor, or
with 50 WM Z-VAD-fmk, a caspase inhibitor (Fig. 4C). We
observed a 63% reduction of cyt c release induced by pacli-
taxel after pretreatment with bongkrekic acid whereas pre-
treatment with Z-VAD-fmk did not modulate the release of
cyt c. On the other hand, doxorubicin-induced release of cyt c,
which occurs with the same kinetics as paclitaxel, was caspase-
Fig. 2. Increase in RR in paclitaxel-treated SK-N-SH cells.
MeansRS.D. of three independent experiments studying the increase
in RR after 1 WM paclitaxel for 1^4 h, 500 nM doxorubicin for 2 h.
*P6 0.05 vs. control (ctrl).
Fig. 3. Early increase in ROS production after paclitaxel treatment. ROS were measured as described in Section 2. Cells were treated with pa-
clitaxel alone for 1^4 h, or for 4 h in combination with 1.5 WM rotenone (Rot) or 1.2 mM KCN, or 50 WM Z-VAD-fmk. Data shown are the
meanRS.D. of at least three experiments performed in quadruplicate. P6 0.05 vs. control (ctrl).
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dependent and PTP-independent. Finally, as additional con-
trol to support the mitochondrial e¡ect of paclitaxel, we tested
the antimitochondrial agent betulinic acid [25], and observed
that it induced the release of cyt c in a caspase-independent
and PTP-dependent manner. Thus, paclitaxel induces a PTP-
dependent cyt c release which occurs upstream of caspase
activation in the same manner as an antimitochondrial agent
does.
4. Discussion
In this study, we demonstrate that the direct mitochondrial
e¡ect of paclitaxel observed in vitro [14,16,17] also occurred in
intact cells. Paclitaxel induces early changes in the morphol-
ogy of mitochondria associated with an increase in both RR
and mitochondrial ROS production. Paclitaxel also triggers
the release of cyt c from mitochondria, upstream of caspase
activation. Involvement of mitochondria starts very early dur-
ing paclitaxel-induced apoptosis (1 h after the beginning of
the treatment) as massive apoptosis of SK-N-SH cells is only
observed after 48 h of treatment with paclitaxel.
The 20% increase in RR observed in paclitaxel-treated cells
is the same as that measured in our cell-free system [14]. This
property is not shared by doxorubicin which does not target
mitochondria or tubulin. The increase in RR could be second-
ary to partial speci¢c uncoupling capacities of paclitaxel. The
increase in ROS production can be related to the increase in
RR [23]. The increase of mitochondrial ROS production that
we measure in SK-N-SH cells is consistent with data from
Su et al. [26] or from Varbiro et al. [16] who showed a 10%
increase in ROS production after paclitaxel treatment (1 WM,
1 h) of the BRA-3A cell line. The role of both the early
increase in ROS production and the increase in RR is still
unclear but analysis of cell viability after 72 h of cotreatment
with paclitaxel and rotenone or KCN (our unpublished data)
indicates that inhibition of mitochondrial ROS production
and of RR decreases paclitaxel-induced cytotoxicity. More-
over, recent reports suggest that changes in RR de¢ne an
Fig. 4. Analysis of cytosolic release of mitochondrial cyt c. A: Western blot analysis of cytosolic cyt c after treatment with 1 WM paclitaxel for
4^48 h. B: Immuno£uorescent analysis of the release of cyt c. C: Percentage of cells with cyt c released from mitochondria after a 24 h incuba-
tion with di¡erent anticancer agents alone or in combination with the PTP inhibitor bongkrekic acid or with the caspase inhibitor Z-VAD-
fmk. *P6 0.05 vs. control (ctrl).
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early pathway for the induction of apoptosis [27] and that
de¢ciency in respiration could lead to a marked resistance
to cyt c release and apoptosis [28]. Thus, the increase in RR
and the early increase in ROS production triggered by pacli-
taxel are very likely to be early pro-apoptotic e¡ects. More-
over, these mitochondrial e¡ects occur for paclitaxel concen-
trations and treatment durations that induce bundling of
microtubules.
Our results clearly indicate that paclitaxel induces cyt c
release in a caspase-independent and PTP-dependent manner
after a 24 h treatment, as betulinic acid, an antimitochondrial
agent, does [25]. In contrast, doxorubicin-induced release of
cyt c is caspase-dependent and PTP-independent [25]. Shimizu
et al. [29] also demonstrated that inhibition of the opening of
the PTP with a VDAC (PTP main component) monoclonal
antibody could almost totally inhibit paclitaxel-induced apo-
ptosis, stressing the importance of the PTP in paclitaxel-
induced cell death.
The paclitaxel-induced cyt c release is compatible with a
direct mitochondrial e¡ect of paclitaxel. Nevertheless, there
is a 24 h delay between the release of cyt c in a cell-free system
and in intact cells. This di¡erence has already been observed
with other PTP inducers [25,30]. Several hypotheses can be
proposed to explain this phenomenon. First, in intact cells,
drugs may have several targets and thus a smaller amount of
drug may be e¡ectively available for mitochondria. Second,
the mitochondrial isolation procedure may also induce
changes in mitochondria, such as translocation of pro-apopto-
tic molecules like Bax or modi¢cation of mitochondrial lipids.
Individually, these changes are not su⁄cient to induce cyt c
release but they may represent the ¢rst step of cyt c release
[31^33]. Lastly, in intact cells, the mitochondrial e¡ect of
drugs may be delayed upon Bcl-2 phosphorylation [34] or
inhibited by cytosolic factors such as p27 [35] or HSP27
[36]. Paclitaxel-induced release of cyt c may also be inhibited
by integrin signaling [37]. These factors could represent resis-
tance factors to chemotherapy. The mechanism of this in-
triguing delay is currently under investigation.
Together with our previous work [14,15,18], these results
strongly suggest that paclitaxel induces apoptosis at least par-
tially via its direct e¡ect on mitochondria, probably upon its
binding to mitochondrial tubulin that is speci¢cally associated
with VDAC.
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